Annals of Oncology· @Annals_Oncology · X·· 1 天前评分70
正文 · 机器翻译
📢 #ESMO26 同步论文：postMONARCH 3 期试验中，abemaciclib + fulvestrant 与 pbo + fulvestrant 相比，在既往接受 CDK4/6 抑制剂 + 内分泌治疗后进展的 HR+、HER2- 晚期乳腺癌患者中的 OS。
🔗https://tinyurl.com/mt82dufd
@KalinskyKevin @BianchiniGP
197 浏览 · 2 赞 · 3 转发 · 0 回复
会议摘要
1RO按 Rapid oral 1: Breast cancer, advanced stage 对上
Overall survival from the phase 3 postMONARCH trial of abemaciclib + fulvestrant vs placebo + fulvestrant for HR+, HER2- advanced breast cancer following progression on a prior CDK4/6 inhibitor + endocrine therapy
https://esmocongress.esmo.org来源：Annals of Oncology · x.com